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Abstract
Background: Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading
glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance. Teicoplanin may represent
an alternative to vancomycin because of its acceptable bone penetration and possible subcutaneous
administration.
Methods: Adults receiving teicoplanin for S. aureus BJI were included in a retrospective cohort study investigating
intravenous or subcutaneous teicoplanin safety and pharmacokinetics.
Results: Sixty-five S. aureus BJIs (orthopedic device-related infections, 69 %; methicillin-resistance, 17 %) were
treated by teicoplanin at the initial dose of 5.7 mg/kg/day (IQR, 4.7–6.5) after a loading dose of 5 injections 12 h
apart. The first trough teicoplanin level (Cmin) reached the therapeutic target (15 mg/L) in 26 % of patients, only. An
overdose (Cmin >25 mg/L) was observed in 16 % patients, 50 % of which had chronic renal failure (p = 0.049). Seven
adverse events occurred in 6 patients (10 %); no predictive factor could be highlighted. After a 91-week follow-up
(IQR, 51–183), 27 treatment failures were observed (42 %), associated with diabetes (OR, 5.1; p = 0.057), systemic
inflammatory disease (OR, 5.6; p = 0.043), and abscess (OR, 4.1; p < 10−3). A normal CRP-value at 1 month was
protective (OR, 0.2; p = 0.029). Subcutaneous administration (n = 14) showed no difference in pharmacokinetics and
tolerance compared to the intravenous route.
Conclusions: Teicoplanin constitutes a well-tolerated therapeutic alternative in S. aureus BJI, with a possible
subcutaneous administration in outpatients. The loading dose might be increase to 9–12 mg/kg to quickly reach
the therapeutic target, but tolerance of such higher doses remains to be evaluated, especially if using the
subcutaneous route.
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Background
Staphylococci are the first etiologic agents of bone and
joint infection (BJI). Methicillin-susceptible Staphylococ-
cus aureus (MSSA) is predominant and antistaphylococ-
cal penicillins such as nafcillin, oxacillin and cloxacillin
are the backbone molecules for the initial antimicrobial
therapy [1, 2]. Nevertheless, glycopeptide alternative, in-
cluding vancomycin or teicoplanin, remains frequently
used for several reasons: i) although hospital diffusion of
methicillin-resistant clones of S. aureus (MRSA) is cur-
rently controlled in France, MRSA still accounts for
20 % of S. aureus isolates involved in BJI [3]; ii) half of
staphylococcal BJI are caused by coagulase negative
staphylococci (CNS), among which methicillin resistance
has continuously increased in the past years to presently
reach 50 % of isolates [3]; and iii) antistaphylococcal
penicillins are the first cause of antimicrobial-related ad-
verse events during long-term treatment of staphylococ-
cal BJI [4], in case of which glycopeptides are the first
alternative. If vancomycin is largely prescribed in this
context, teicoplanin could theoretically represent an ac-
ceptable alternative in BJI as studies have shown a com-
parable efficacy compared to vancomycin in various
other conditions [5] and an improved safety profile with
fewer renal toxicity [6], as well as the possibility of daily
subcutaneous injection, of particular interest for out-
patient parenteral antimicrobial therapy (OPAT). In
addition, various studies have shown that teicoplanin
pharmacodynamic profile was superior compared to
vancomycin regarding bone diffusion [7, 8]. Few studies
have investigated the use of teicoplanin in BJI, particu-
larly through subcutaneous administration. The present
study assesses the efficacy and tolerance of teicoplanin
in S. aureus BJI, especially focusing on subcutaneous
use.
Methods
Inclusion criteria and data collection
A retrospective single-center observational cohort study
(2001 to 2011) was conducted including all consecutive
patients managed at our institution receiving teicoplanin
as part of S. aureus BJI treatment. Patients diagnosed with
staphylococcal BJI were identified by cross-referencing the
prospective maintained databases of the regional referral
center for BJI and the bacteriology laboratory, which list
exhaustively all strains isolated from osteoarticular sam-
ples since 2001. Patients with diabetic foot- and decubitus
ulcer-related BJI were excluded, as they require a specific
management [9]. If patients presented more than one
osteoarticular infected site, they were considered as inde-
pendent events for cohort description and outcome ana-
lysis, but pooled for tolerance and pharmacologic
evaluation. For each patient, data were collected from
medical records, nursing charts and biological software in
an anonymous standardized case report form. All available
trough teicoplanin plasmatic levels (Cmin) in the first
14 days of treatment were recorded.
Definitions
BJI diagnosis was based upon the existence of clinical and
biological evidences of infection, and at least one reliable
bacteriological sample positive for S. aureus (i.e., percu-
taneous joint fluid aspiration, surgical sample, and/or
blood culture). BJI were classified according to: i) the ex-
istence of orthopedic implant (i.e. joint prosthesis, periph-
eral or vertebral osteosynthesis); and ii) progression of
infection, differentiating acute (≤3 weeks) versus chronic
(>3 weeks) infection, calculated from the presumed date
of inoculation (i.e., date of device implantation for postop-
erative orthopaedic device-related infection (ODI), or date
of symptom onset for native BJI) up to diagnosis.
The modified Charlson’s comorbidity index was calcu-
lated as previously described [10]. Immunosuppression
was defined as: i) corticosteroid therapy >10 mg of pred-
nisone per day or equivalent for at least 3 months; ii)
immunosuppressive drug(s) during the two last months
before BJI onset; or iii) chemotherapy for hematological
malignancy or solid tumor.
A Cmin >15 mg/L was taken as an acceptable thera-
peutic target. Patients with a Cmin >25 mg/L were con-
sidered as overexposure.
Teicoplanin-related adverse events (AE) occurring
during follow-up were notified and classified according
to the Common Terminology Criteria for Adverse
Events (CTCAE, National Cancer Institute, 2003). Teico-
planin accountability in the AE occurrence was left to
the clinician appreciation, with the help of a pharmacov-
igilance specialist in doubtful cases.
Treatment failure was defined as persisting infection
under appropriate antimicrobial therapy, relapse after
the interruption of antimicrobial therapy, necessity of
surgical revision on the account of persisting septic
focus ≥5 days after the first intervention, superinfections,
and/or fatal outcome if BJI-related.
Teicoplanin administration
For intravenous (IV) administration, each dose was di-
luted in 100 mL of isotonic saline solution and adminis-
trated over a 30-min period. For subcutaneous (SC)
injections, each dose was diluted in 50 mL of isotonic
saline solution and delivered by a nurse during a 30- to
60-min gravity infusion using a butterfly disposable
needle.
Statistical analysis
Descriptive statistics were used to estimate the frequen-
cies of the study variables, described as percentages (%)
for dichotomous variables, and medians (interquartile
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range (IQR)) for continuous variables. For the percent-
age calculation of each variable, the number of missing
values was excluded from the denominator. Non-
parametric statistical methods were used to compare the
study groups (Chi-squared test, Fisher exact test and
Mann–Whitney U test), as appropriate. Determinants of
teicoplanin-related AE and treatment failure were
assessed using binary logistic regression, including the
clinically relevant variables in each model, and expressed
by their Odd ratio (OR) and 95 % confidence intervals
(95 % CI). Clinically pertinent variables with a p-value
<0.15 in the univariate analysis were included in the final
multivariate models. A value of p <0.05 was considered
as significant. All analyses were performed using SPSS
software version 19.0 (SPSS, Chicago, IL).
Results
Population characteristics
Sixty patients were included (34 male, 56.7 %; median
age, 62 years (interquartile range (IQR), 48-75),
among who two and one presented three and two
concomitant infected osteoarticular site, respectively.
Consequently, a total of 65 episodes of BJI were ana-
lyzed, including 20 (30.8 %) native and 45 (69.2 %)
orthopedic device-related (ODI) infections, and 23
(35.4 %) chronic infections. A MRSA was implicated
in 11 (16.9 %) cases and 17 (26.2 %) infections were
plurimicrobial. All staphylococcal isolates were sus-
ceptible to teicoplanin. A surgical procedure was per-
formed in 50 (76.9 %) cases, predominantly in ODI
(93.3 %). All patients were initially treated by a com-
bination antimicrobial therapy. Median total duration
of treatment was 26.8 (IQR, 17.7–42.8) weeks. Pa-
tients’ characteristics are described in Table 1.
Teicoplanin prescription modalities
Teicoplanin was used at the median dose of 5.7 (IQR,
4.7–6.5) mg/kg administrated in a single daily injection,
after a loading dose (n = 55, 85.9 %) of 5 (IQR, 5–5) in-
jections of 5.7 (IQR, 4.7–6.5) mg/kg/12 h. Median total
duration of teicoplanin therapy was 6.0 (IQR, 2.7–9.9)
weeks. Teicoplanin was mostly administrated via IV
route (n = 51, 78.5 %), but 14 (21.5 %) cases were treated
by SC route with no difference regarding prescription
modalities (median dose, loading dose, duration) com-
pared with IV-treated patients (Table 1). The median
number of SC injections per patient was 39.5 (IQR,
24.0–86.5), with a maximum of 600 mg of teicoplanin
per injection. Seven switches in administration route
were observed, all in patients initially receiving IV treat-
ment. The main teicoplanin companion drugs were
fluoroquinolones (44.6 %), rifampicin (24.6 %) and pristi-
namycin (16.9 %).
Pharmacological data
During the first 14 days of treatment, at least one Cmin
value was available in 59 patients, in whom a median of 2
(IQR, 2─3) dosages was performed during this period.
An early Cmin (on day 3, 4 or 5) was available in 44 pa-
tients and was under the therapeutic target of 15 mg/L in
73.5 % of them, with a median value of 11.7 mg/L. A Cmin
>15 mg/L was finally obtained in only 39 (66.1 %) patients
within the first 2 weeks of treatment, in a median delay of
9 (IQR, 6─13) days, without difference between the IV
and SC routes of administration (Fig. 1). No difference
was observed between patients who reached or not the
therapeutic target of 15 mg/L (Additional file 1: Table S1).
During the first 2 weeks of treatment, an overexposure
was observed in 8 patients who had a significantly older age
(76.0 year-old, p = 0.007) and modified Charlson
comorbidity index (7.5, p = 0.001) than those with no over-
exposure (Additional file 1: Table S1). Their baseline renal
function was more frequently impaired (50.0 %, p = 0.049).
Tolerance
Seven adverse events occurred in 6 (10.0 %) of the 60 in-
cluded patients, consisting in 5 cutaneous rashes, 1 epi-
sode of headache, and one pancytopenia (Table 2). IV
and SC routes were implicated in four and one cases,
respectively (p = 0.617). No difference was shown be-
tween patients presenting or not a teicoplanin-related
AE, and no predictive factor could be highlighted and
especially chronic renal failure, daily dose and early
overdose (Additional file 2: Table S2). Of note, no severe
AE was reported at the injection site in the SC group.
The occurrence of an adverse event did not significantly
impact outcome.
Outcome
In a median follow-up of 91.1 (IQR, 50.6–182.6) weeks,
27 treatment failure were observed, including persisting
infections (n = 18; 66.7 %), relapses (n = 6; 22.2 %) and/
or superinfections (n = 13; 48.1 %), leading to iterative
surgical procedure(s) in 23 (35.4 %) cases including two
limb amputations. One sepsis-related death was
observed.
In univariate analysis, pertinent variables associated with
therapeutic failure with a p-value <0.15 were inflammatory
systemic disease (OR, 5.600; 95 % CI, 1.056–29.683),
diabetes mellitus (OR, 5.143; 95 % CI, 0.951–27.826), and
abscess (OR, 4.073; 95 % CI, 1.420–11.684). The return to
baseline C-reactive protein value at 1 month was associ-
ated with a lower risk of treatment failure (OR, 0.214; 95
% CI, 0.051–0.852). In multivariate analysis, in situ abscess
was independently associated with treatment failure (OR,
3.641; 95 % CI, 1.110–11.944) (Additional file 3: Table S3).
Of note, teicoplanin administration route did not influ-
ence the outcome.
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Sex (male) 34 (52.3 %) 27 (52.9 %) 7 (50.0 %) 1.000
Age (year-old) 61.8 (49.0–74.0) 61.8 (52.1–73.8) 59.1 (39.1–75.5) 0.678
Comorbidities
Modified CCI 3 (1–5) 3 (2–5) 1.5 (0.3–5.8) 0.478
BMI (kg/m2) 27.0 (21.6–29.7) 27.8 (22.0–31.6) 24.7 (20.7–28.0) 0.154
Obesity (BMI > 30) 14 (22.2 %) 13 (26.5 %) 1 (7.1 %) 0.116
Diabetes 8 (12.3 %) 7 (13.7 %) 1 (7.1 %) 0.447
Immunosuppression 11 (16.9 %) 10 (19.6 %) 1 (7.1 %) 0.253
Chronic renal failure 9 (14.8 %) 6 (12.8 %) 3 (21.4 %) 0.338
Chronic hepatic disease 2 (3.3 %) 2 (4.3 %) 0 (0 %) 0.591
Chronic pulmonary disease 15 (24.6 %) 10 (21.3 %) 5 (35.7 %) 0.223
Congestive heart failure 5 (8.1 %) 3 (6.3 %) 2 (14.3 %) 0.314
Cerebrovascular disease 4 (6.6 %) 1 (2.1 %) 3 (21.4 %) 0.035
Peripheral artery disease 5 (8.2 %) 4 (8.5 %) 1 (7.1 %) 0.678
Neoplasic disease 6 (9.8 %) 6 (12.8 %) 0 (0 %) 0.193
Malignant hemopathy 1 (1.5 %) 1 (2.0 %) 0 (0 %) 0.785
Inflammatory systemic disease 9 (14.8 %) 9 (19.1 %) 0 (0 %) 0.079
Dementia 2 (3.1 %) 2 (3.9 %) 0 (0 %) 0.613
BJI types
Native BJI 20 (30.8 %) 16 (31.4 %) 4 (28.6 %) 0.559
Incl. arthritis 5 (25 %) 4 (25.0 %) 1 (25.0 %) 0.708
Incl. osteomyelitis 5 (25 %) 5 (31.3 %) 0 (0 %) 0.284
Incl. vertebral osteomyelitis 10 (50 %) 7 (43.8 %) 3 (75.0 %) 0.367
ODI 45 (69.2 %) 35 (68.6 %) 10 (71.4 %) 0.559
Incl. PJI 34 (75.6 %) 28 (80.0 %) 6 (60.0 %) 0.187
Incl peripheral osteosynthesis 8 (17.8 %) 6 (17.1 %) 2 (20.0 %) 0.579
Incl. vertebral osteosynthesis 3 (6.7 %) 1 (2.9 %) 2 (20.0 %) 0.119
BJI characteristics
Evolution delay (weeks) 1.6 (0.1–6.7) 1.6 (0.4–9.2) 0.9 (0.2–3.1) 0.299
Chronic BJI (> 3 weeks) 23 (35.4 %) 19 (37.3 %) 4 (28.6 %) 0.754
Mechanism
Hematogenous 30 (46.2 %) 24 (47.1 %) 6 (42.9 %) 1.000
Inoculation 32 (49.2 %) 25 (49.0 %) 7 (50.0 %) 1.000
Contiguity 3 (4.6 %) 2 (3.9 %) 1 (7.1 %) 0.523
MRSA 11 (16.9 %) 9 (17.6 %) 2 (14.3 %) 1.000
Plurimicrobial infection 17 (26.2 %) 16 (31.4 %) 1 (7.1 %) 0.062
Biological inflammatory syndrom 61 (95.3 %) 47 (91.0 %) 14 (100 %) 1.000
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Table 1 Description of the 65 included episodes of BJI and comparison between the intravenous and subcutaneous routes of
administration (Continued)
Maximal CRP value (mg/L) 164 (92–234.3) 160.2 (86.8–300.0) 264.7 (143.2–332.0) 0.245
Local and general complications
Abscess 26 (40.0 %) 22 (43.1 %) 4 (28.6 %) 0.252
Sinus tract 23 (35.4 %) 21 (41.2 %) 2 (14.3 %) 0.056
Infective endocarditis 2 (3.7 %) 2 (4.8 %) 0 (0 %) 1.000
Hospitalization
Length of stay (weeks) 5.6 (1.9–8.9) 5.8 (2.3–8.9) 3.8 (1.6–8.1) 0.580
Surgical management 50 (76.9 %) 38 (74.5 %) 12 (85.7 %) 0.491
Debridement (native BJI) 8 (40.0 %) 5 (31.3 %) 3 (75.0 %) 0.153
Conservative procedurea 24 (53.3 %) 20 (57.1 %) 4 (40.0 %) 0.274
One-stage exchangea 3 (6.7 %) 2 (5.7 %) 1 (10.0 %) 0.539
Two-stage exchangea 15 (33.3 %) 11 (31.4 %) 4 (40.0 %) 0.440
Antimicrobial therapy
Total duration (weeks) 26.8 (17.7–42.8) 26.2 (17.9–41.6) 28.4 (17.8–48.4) 0.406
Parenteral treatment 64 (98.5 %) 50 (98.0 %) 14 (100 %) 1.000
Duration (weeks) 9.4 (5.9–24.4) 9.4 (6.3–25.1) 10.4 (4.4–16.1) 0.790
Combination therapy 65 (100 %) 51 (100 %) 14 (100 %) NC
Duration (weeks) 25.7 (16.4–45.1) 25.6 (15.9–44.3) 27.6 (21.3–43.2) 0.442
Teicoplanin use
IV route 51 (78.5 %) NA NA NA
Loading dose 55 (85.9 %) 44 588.0 %) 11 (78.6 %) 0.521
Loading dose (mg/kg/12 h) 5.7 (4.7–6.5) 5.6 (4.7–6.5) 6.0 (5.4–6.7) 0.218
Number of injections 5 (5–5) 5 (5–5) 5 (5–5)
Maintenance dose (mg/kg/24 h) 5.7 (4.7–6.5) 5.6 (4.7–6.5) 5.9 (5.1–6.8) 0.406
Administration route switch 7 (10.8 %) 7 (13.7 %) 0 (0 %) 0.164
Duration of treatment
Total duration (weeks) 6.0 (2.7–9.9) 6.0 (2.9–9.7) 5.8 (3.0–11.6 0.750
IV treatment duration (weeks) 5.0 (2.9–9.7) 5.0 (3.0–9.7) NA NA
SC treatment duration (weeks) 6.2 (3.9–21.4) NA 5.3 (2.8–11.6) NA
Pharmacological data
Number of dosages 2.5 (2–3.3) 3 (2–3) 2 (2–3.8) 0.891
Initial Cmin (day 3 to 5, mg/L) 11.7 (9.2–16.3) 10.8 (8.6–15.2) 13.8 (11.4–16.2) 0.130
Initial Cmin >25 mg/L 0 (0 %) 0 (0 %) 0 (0 %) NC
Initial Cmin <15 mg/L 36 (73.5 %) 29 (74.4 %) 7 (70.0 %) 1.000
Overdose (day 1 to 14) 10 (15.6 %) 8 (16.0 %) 2 (14.3 %) 1.000
Delay for Cmin > 15 mg/L (days) 8.5 (6–13) 9 (6–13) 7 (4.5–9.5) 0.259
Companion drugs
Rifampicin 16 (24.6 %) 12 (23.5 %) 4 (28.6 %) 0.732
Fluoroquinolone 29 (44.6 %) 20 (39.2 %) 9 (64.3 %) 0.131
Pristinamycin 11 (16.9 %) 11 (21.6 %) 0 (0 %) 0.102
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Discussion
Although teicoplanin is among the drugs of choice for
the treatment of staphylococcal BJI, efficacy, safety and
pharmacokinetics data in that specific setting are scarce.
Thus, the present study provides relevant features with
regards to staphylococcal BJI management. Our study is
subjected to limitations BJI studies generally encounter
such as the retrospective design coupled to the inherent
lack of control patients. The limited patients’ recruit-
ment, the variety of infection types, surgical manage-
ment and medical treatment approaches also constitute
a limitation to generalisation.
These current difficulties in the field of BJI explain the
limited and controversial data available on the efficacy of
teicoplanin in staphylococcal BJI. In past studies, treat-
ment success rate ranged from 53 to 91 % [11–14]. The
low success rate observed in our study (60 %) may be ex-
plained by several factors. First, there is a significant selec-
tion bias as patients were recruited in a reference center
dedicated to manage complex BJI with a high-risk of fail-
ure. In addition, most of past studies included native BJI
with a relatively short follow-up (<1 year). Finally,
pharmacodynamics parameters may impact the outcome
[15, 16]. In our study, a Cmin reaching the therapeutic tar-
get of 15 mg/L was achieved in a quarter of cases at the
first measurement (day 3 to 5) and in two thirds of pa-
tients within 2 weeks of treatment. The use of higher
doses may improve these pharmacological parameters. In
Table 1 Description of the 65 included episodes of BJI and comparison between the intravenous and subcutaneous routes of
administration (Continued)
Teicoplanin-related AE 6 (10 %) 4 (8.7 %) 2 (14.3 %) 0.617
Follow-up and outcome
Follow-up period (weeks) 91.1 (50.6–182.6) 98.0 (58.3–194.9) 68.2 (40.7–100.3) 0.112
One-month CRP level < 10 mg/L 17 (27.9 %) 14 (28.0 %) 3 (27.3 %) 1.000
Treatment failure 27 (41.5 %) 21 (41.2 %) 6 (42.9 %) 1.000
Persisting infection 18 (28.6 %) 14 (28.0 %) 4 (30.8 %) 1.000
Relapse 6 (9.7 %) 6 (12.2 %) 0 (0 %) 0.328
Iterative surgery 23 (35.9 %) 19 (38.0 %) 4 (28.6 %) 0.754
BJI-related death 1 (1.6 %) 1 (2.0 %) 0 (0 %) 1.000
Superinfection 13 (20.0 %) 10 (19.6 %) 3 (21.4 %) 1.000
AE adverse event, BJI bone and joint infection, BMI body mass index, CCI Charlson’s comorbidity index, Cmin plasmatic teicoplanin trough concentration, CRP C-
reactive protein, Incl Including, IV Intravenous, MRSA Methicillin-resistant Staphylococcus aureus, ODI orthopedic device-associated infection, PJI prosthetic joint in-
fection, SC subcutaneous
a for orthopedic device-related infections
Fig. 1 Comparison of median teicoplanin trough concentrations in intravenously- and subcutaneously-treated patients during the first 2 weeks of
treatment. Data are presented as median and interquartile ranges of teicoplanin trough levels available each day after treatment initiation
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the study by LeFrock et al, the teicoplanin Cmin averaged
10 mg/L after 6 days in patients receiving 6 mg/kg/day
after 5 loading doses of 6 mg/kg/12 h compared to 20 mg/
L from the third day in patients receiving 12 mg/kg/day
after 5 loading doses of 12 mg/kg/12 h [12]. If no differ-
ence was observed regarding osteomyelitis outcome,
higher doses were associated with a better outcome
among patients with native septic arthritis. Nevertheless,
clinical outcome according to Cmin was not an intended
end-point in the study. Greenberg et al reported a favor-
able outcome in patients with a Cmin > 30 mg/L, but with
no comparative data [17]. It is our belief that the loading
dose should be increased to 8 mg/kg/12 h to optimize
trough concentrations, particularly in case when ortho-
pedic implant is retained. Other determinants of thera-
peutic success had already been described, such as
inflammatory systemic disease, diabetes and abscess [18,
19]. Conversely, our study was not associated with MRSA
as a negative prognostic factor as found elsewhere [20].
This last prognostic factor probably relies on the benefit
of receiving anti-staphylococcal penicillins for a MSSA
compared to glycopeptides [21, 22], which could not be
highlighted in our series as all patients received teicopla-
nin, including those with MSSA infection. Finally, al-
though all S. aureus isolates included in our study were
tested susceptible to teicoplanin [23], the exact MIC of
each isolate was not available and could consequently not
be challenged as an outcome predictor. As described with
vancomycin, high teicoplanin MICs (i.e., > 1.5 mg/L) have
been associated with unfavorable outcome and higher
mortality rate among teicoplanin-treated MRSA
bacteremia [24].
Regarding safety data, our results highlighted an excel-
lent tolerance of teicoplanin with a 10 % incidence of
AE, which is consistent with the toxicity rate of 9 to
18 % observed in other similar studies [11, 13, 25].
However, the incidence of AE was probably been under-
estimated due to the retrospective nature of our study
(memory bias for non-severe AE). Indeed, in the pro-
spective study of LeFrock et al, the rate of AE was 35 %,
requiring discontinuation of treatment in 17 % of the
cases [12]. Very few data support enhanced AE related
to teicoplanin dose increase [26]. LeFrock et al reported
fever in 5.6 and 13.1 % of patients receiving 6 and
12 mg/kg/day of teicoplanin, respectively, with similar
data regarding cutaneous rashes (7.6 and 15.4 %, re-
spectively) [12]. In our study, teicoplanin daily dose and
overexposure within 2 weeks of treatment were not pre-
dictors of AE. In two other studies, a dose increase from
400 to 600 mg/day was not associated with an increased
risk of toxicity [27, 28].
The description of subcutaneous administration of tei-
coplanin is another important highlight of our study,
showing similar efficacy, safety and pharmacokinetics
characteristics compared to IV administration. The retro-
spective design may result in underestimating non-serious
AE such as injection site reactions. In a recent prospective
evaluation of SC teicoplanin in 30 patients, 90 % of pa-
tients presented moderate local AE (grades 1–2) and no
severe local reaction (grade ≥3) [29]. Of note, none of our
patients had SC teicoplanin infusion exceeding 600 mg,
reported as an independent risk factor for local reaction in
the study by El Samad et al [29]. Subcutaneous teicoplanin
may be particularly useful in patients with BJI eligible for
OPAT achieving efficacy and allowing cost reduction [30,
31]. Some authors have even proposed a 3-injections
weekly regimen with a satisfactory success rate and an es-
timated saving of $60,000 per episode of BJI [32, 33].
However, a study has tempered this suggestion by showing
a non-significant trend toward a higher risk of failure in
patients treated by teicoplanin for BJI [34]. Further stud-
ies, optimally with a prospective and controlled design,
Table 2 Description of the seven teicoplanin-related adverse events observed in 6 of the 60 included patients
Case Modified
CCI
BJI type AE subtype CTCAE
grade









2 IV 12 mg/L 7 days None Yes Yes (3 days) Yes
2 4 Acute PJI Rash maculo-
papular
2 IV No 10 days Oxacillin
Clindamycin
Yes No (17 days) Yes
3 0 Acute VO Rash maculo-
papular
Pancytopenia
3 SC No 11 days Rifampicin Yes No Yes
4 5 Chronic
osteomyelitis
Headache 1 IV 27.8 mg/
L
20 days Rifampicin Yes No Yes
5 2 Chronic VO Rash maculo-
papular
3 SC No 22 days Ofloxacin Yes Yes (4 days) Yes
6 2 Acute VO Rash maculo-
papular
2 IV No 14 days Ofloxacin Yes No Yes
AE adverse event, BJI bone and joint infection, CCI Charlson’s comorbidity index, CTCAE common terminology criteria for adverse events, IV Intravenous, PJI
prosthetic joint infection, SC subcutaneous, VO vertebral osteomyelitis
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are warranted to assess both the risk-benefit as well as the
cost-benefit of teicoplanin in staphylococcal BJI.
Conclusion
At the dose of 6 mg/kg/24 h after a loading dose of 5 in-
jections of 6 mg/kg/12 h, teicoplanin appeared as a well-
tolerated option in the treatment of S. aureus BJI, and
may be recommended as an alternative to vancomycin
in patients with MRSA infection or with intolerance to
betalactam antibiotics. The use of higher doses must be
discussed in order to optimize pharmacokinetic parame-
ters of which clinical pertinence remains to be demon-
strated. However, we believe that the loading dose
should be increased to more rapidly reach the thera-
peutic target, which can be crucial for outcome of acute
ODI with implant retention. Furthermore, subcutaneous
administration of teicoplanin showed similar results in
terms of efficacy, tolerance and pharmacokinetics com-
pared to the intravenous administration, which encour-
age its use in OPAT. However, the implication of a
multidisciplinary referral center for the management of
complex BJI is needed to ensure a successful outpatient
management, as suggested by the need for a close clin-
ical, biological and pharmacological monitoring, particu-
larly during the first 2 weeks of treatment when the
majority of side effects occur.
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